{"id":2898,"date":"2017-09-28T08:03:14","date_gmt":"2017-09-28T12:03:14","guid":{"rendered":"https:\/\/www.stockcalc.com\/blog\/BrianD\/?p=2898"},"modified":"2017-09-28T08:03:14","modified_gmt":"2017-09-28T12:03:14","slug":"regeneron-pharmaceuticals-regnnas-and-shire-shpgnas-are-undervalued","status":"publish","type":"post","link":"https:\/\/www.stockcalc.com\/blog\/BrianD\/2017\/09\/28\/regeneron-pharmaceuticals-regnnas-and-shire-shpgnas-are-undervalued\/","title":{"rendered":"Regeneron Pharmaceuticals (REGN:NAS) and Shire (SHPG:NAS) Are Undervalued"},"content":{"rendered":"

Stockcalc – Free Trial<\/h4>\n

Have a free look inside the StockCalc website at www.stockcalc.com<\/a><\/p>\n

\n
\n<\/hr>\n

I have used the analysis tools on the website stockcalc.com<\/a> to generate some of the content of this blog post. These tools and reports are available for free at www.stockcalc.com\/TopPicks.aspx<\/a>.<\/p>\n

Undervalued Stocks on NASDAQ<\/h4>\n

Today we are looking at companies that are considered undervalued based on the Analyst data in the StockCalc database.<\/p>\n

In the table below we can see the close price and target price for these companies along with the number of analysts covering the stock. We also have included the fiscal year for the target price as sometimes these analyst targets are not for the current or even the next fiscal year.<\/p>\n

There can be a number of reasons why a company would be on this list. What is particularly interesting are companies with a large analyst following that make this list. We need to dig deeper into these companies to understand why the difference in price versus target.<\/p>\n

Today’s Data on NASDAQ<\/h4>\n

Today’s data is for companies listed on the NASDAQ<\/strong>.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Symbol<\/th>\nName<\/th>\nTarget Year<\/th>\nClose Price<\/th>\nTarget Price Mean<\/th>\nCurrency<\/th>\nTarget Price # of Estimates<\/th>\n<\/tr>\n
GOOG<\/td>\nAlphabet Inc<\/td>\n2018<\/td>\n924.860000<\/td>\n1081.5000<\/td>\nUSD<\/td>\n10<\/td>\n<\/tr>\n
GOOGL<\/td>\nAlphabet Inc<\/td>\n2018<\/td>\n937.430000<\/td>\n1081.5000<\/td>\nUSD<\/td>\n10<\/td>\n<\/tr>\n
AMZN<\/td>\nAmazon.com Inc<\/td>\n2018<\/td>\n938.600000<\/td>\n1163.1970<\/td>\nUSD<\/td>\n11<\/td>\n<\/tr>\n
AVGO<\/td>\nBroadcom Ltd<\/td>\n2018<\/td>\n237.270000<\/td>\n287.7778<\/td>\nUSD<\/td>\n9<\/td>\n<\/tr>\n
CHTR<\/td>\nCharter Communications Inc<\/td>\n2018<\/td>\n359.040000<\/td>\n406.2500<\/td>\nUSD<\/td>\n4<\/td>\n<\/tr>\n
PCLN<\/td>\nThe Priceline Group Inc<\/td>\n2018<\/td>\n1825.920000<\/td>\n2059.0000<\/td>\nUSD<\/td>\n5<\/td>\n<\/tr>\n
REGN<\/td>\nRegeneron Pharmaceuticals Inc<\/td>\n2018<\/td>\n434.970000<\/td>\n516.4000<\/td>\nUSD<\/td>\n5<\/td>\n<\/tr>\n
SHPG<\/td>\nShire PLC<\/td>\n2018<\/td>\n150.700000<\/td>\n236.0190<\/td>\nUSD<\/td>\n5<\/td>\n<\/tr>\n
EQIX<\/td>\nEquinix Inc<\/td>\n2018<\/td>\n434.420000<\/td>\n500.6667<\/td>\nUSD<\/td>\n3<\/td>\n<\/tr>\n
EXPE<\/td>\nExpedia Inc<\/td>\n2018<\/td>\n143.390000<\/td>\n175.8333<\/td>\nUSD<\/td>\n6<\/td>\n<\/tr>\n
CHKP<\/td>\nCheck Point Software Technologies Ltd<\/td>\n2018<\/td>\n111.740000<\/td>\n181.8750<\/td>\nUSD<\/td>\n8<\/td>\n<\/tr>\n
TSRO<\/td>\nTesaro Inc<\/td>\n2018<\/td>\n118.400000<\/td>\n150.0000<\/td>\nUSD<\/td>\n4<\/td>\n<\/tr>\n
COHR<\/td>\nCoherent Inc<\/td>\n2018<\/td>\n242.040000<\/td>\n309.6667<\/td>\nUSD<\/td>\n3<\/td>\n<\/tr>\n
LOGM<\/td>\nLogMeIn Inc<\/td>\n2018<\/td>\n107.950000<\/td>\n140.0000<\/td>\nUSD<\/td>\n1<\/td>\n<\/tr>\n
RGLD<\/td>\nRoyal Gold Inc<\/td>\n2018<\/td>\n87.930000<\/td>\n119.7877<\/td>\nCAD<\/td>\n2<\/td>\n<\/tr>\n
ULTI<\/td>\nThe Ultimate Software Group Inc<\/td>\n2018<\/td>\n183.210000<\/td>\n226.2000<\/td>\nUSD<\/td>\n5<\/td>\n<\/tr>\n
NBIX<\/td>\nNeurocrine Biosciences Inc<\/td>\n2018<\/td>\n57.450000<\/td>\n89.0000<\/td>\nUSD<\/td>\n3<\/td>\n<\/tr>\n
ATHN<\/td>\nathenahealth Inc<\/td>\n2018<\/td>\n120.240000<\/td>\n156.0000<\/td>\nUSD<\/td>\n6<\/td>\n<\/tr>\n
CBRL<\/td>\nCracker Barrel Old Country Store Inc<\/td>\n2018<\/td>\n146.710000<\/td>\n181.0000<\/td>\nUSD<\/td>\n1<\/td>\n<\/tr>\n
SAGE<\/td>\nSage Therapeutics Inc<\/td>\n2018<\/td>\n63.210000<\/td>\n94.6667<\/td>\nUSD<\/td>\n3<\/td>\n<\/tr>\n
RDUS<\/td>\nRadius Health Inc<\/td>\n2018<\/td>\n36.480000<\/td>\n71.5000<\/td>\nUSD<\/td>\n2<\/td>\n<\/tr>\n
ICPT<\/td>\nIntercept Pharmaceuticals Inc<\/td>\n2018<\/td>\n58.840000<\/td>\n178.5000<\/td>\nUSD<\/td>\n4<\/td>\n<\/tr>\n
HSKA<\/td>\nHeska Corp<\/td>\n2018<\/td>\n85.330000<\/td>\n117.5000<\/td>\nUSD<\/td>\n2<\/td>\n<\/tr>\n
MDGL<\/td>\nMadrigal Pharmaceuticals Inc<\/td>\n2018<\/td>\n33.340000<\/td>\n65.0000<\/td>\nUSD<\/td>\n1<\/td>\n<\/tr>\n
ALBO<\/td>\nAlbireo Pharma Inc<\/td>\n2018<\/td>\n20.680000<\/td>\n58.0000<\/td>\nUSD<\/td>\n1<\/td>\n<\/tr>\n<\/table>\n

Let’s look at a few companies…<\/h4>\n

Lets look at a couple of the companies on this list to get a better understanding of them.<\/p>\n

REGN:NAS Regeneron Pharmaceuticals<\/h6>\n

http:\/\/www.regeneron.com<\/a>
\nRegeneron Pharmaceuticals has 5400 employees and is headquartered in United States.
\nRegeneron Pharmaceuticals Inc is an integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.<\/p>\n

SHPG:NAS Shire<\/h6>\n

http:\/\/www.shire.com<\/a>
\nShire has 23906 employees and is headquartered in Ireland.
\nShire PLC is a biotechnology company focused mainly in the research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions.<\/p>\n

Free Valuation<\/h4>\n

Run a valuation on any of the companies listed above at www.stockcalc.com\/valureport.aspx<\/a> or subscribe at our Stockcalc Facebook Page to receive this list each day Stockcalc Reports<\/a>.<\/p>\n

The content presented here is in part from the website stockcalc.com<\/a> and is provided on an as is<\/strong> or as available<\/strong> basis with all faults and may not be current in all cases. You should not rely on any of the information as authoritative or as a substitute for the exercise of your own skill and judgment in making an investment decision.<\/em><\/p>\n

<\/div>\n
\n

Wait! We want you to try StockCalc for<\/span><\/h2>\n

5 Free Days <\/h1>\n

Yes, I want to find out what my stocks are worth<\/span><\/a>
\n No, I don’t want to know the value of my stocks<\/span><\/a>\n <\/div>\n